[go: up one dir, main page]

WO2012019428A8 - 二苯甲醇类衍生物、其制备方法及其在医药上的应用 - Google Patents

二苯甲醇类衍生物、其制备方法及其在医药上的应用 Download PDF

Info

Publication number
WO2012019428A8
WO2012019428A8 PCT/CN2011/001252 CN2011001252W WO2012019428A8 WO 2012019428 A8 WO2012019428 A8 WO 2012019428A8 CN 2011001252 W CN2011001252 W CN 2011001252W WO 2012019428 A8 WO2012019428 A8 WO 2012019428A8
Authority
WO
WIPO (PCT)
Prior art keywords
derivatives
benzohydrol
pharmaceutical use
preparation process
rennin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2011/001252
Other languages
English (en)
French (fr)
Other versions
WO2012019428A1 (zh
Inventor
邓炳初
吴清泉
吴晓
郑震
嵇雯浩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Priority to CN201180005039.7A priority Critical patent/CN102958912B/zh
Priority to TW100141561A priority patent/TW201242594A/zh
Publication of WO2012019428A1 publication Critical patent/WO2012019428A1/zh
Publication of WO2012019428A8 publication Critical patent/WO2012019428A8/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06Esters of carbamic acids
    • C07C271/08Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/16Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D309/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PCT/CN2011/001252 2010-08-10 2011-08-01 二苯甲醇类衍生物、其制备方法及其在医药上的应用 Ceased WO2012019428A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN201180005039.7A CN102958912B (zh) 2010-08-10 2011-08-01 二苯甲醇类衍生物、其制备方法及其在医药上的应用
TW100141561A TW201242594A (en) 2011-04-25 2011-11-15 Diphenylmethanol derivatives, preparation process and pharmaceutical use thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN201010249629 2010-08-10
CN201010249629.1 2010-08-10
CN201110112168.8 2011-04-25
CN2011101121688A CN102372653A (zh) 2010-08-10 2011-04-25 二苯甲醇类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
WO2012019428A1 WO2012019428A1 (zh) 2012-02-16
WO2012019428A8 true WO2012019428A8 (zh) 2012-05-10

Family

ID=45567316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2011/001252 Ceased WO2012019428A1 (zh) 2010-08-10 2011-08-01 二苯甲醇类衍生物、其制备方法及其在医药上的应用

Country Status (2)

Country Link
CN (2) CN102372653A (zh)
WO (1) WO2012019428A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107098876B (zh) * 2016-02-23 2021-04-06 江苏恒瑞医药股份有限公司 苯基丙酰胺类衍生物、其制备方法及其在医药上的应用
UY38367A (es) 2018-09-13 2020-04-30 Syngenta Participations Ag Compuestos de azol-amida pesticidamente activos
EP4003973B1 (en) 2019-07-23 2024-11-20 Bayer Aktiengesellschaft Novel heteroaryl-triazole compounds as pesticides
TW202136248A (zh) 2019-11-25 2021-10-01 德商拜耳廠股份有限公司 作為殺蟲劑之新穎雜芳基-三唑化合物
CN116082181B (zh) * 2022-12-12 2025-03-04 爱斯特(成都)生物制药股份有限公司 一种制备3-氨基-5-乙氧基-苯甲酸的方法
CN116514673A (zh) * 2023-05-10 2023-08-01 上海慧聚药业有限公司 取代苯胺类化合物的合成

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0419361D0 (en) * 2004-08-31 2004-10-06 Novartis Ag Organic compounds
MX2007003858A (es) * 2004-10-07 2007-12-11 Vitae Pharmaceuticals Inc Diaminoalcanos inhibidores de proteasa asparticas.
US20100160424A1 (en) * 2007-06-20 2010-06-24 Baldwin John J Renin inhibitors
CA2696689A1 (en) * 2007-08-20 2009-02-26 Merck Frosst Canada Ltd. Renin inhibitors
JP5441705B2 (ja) * 2007-10-15 2014-03-12 武田薬品工業株式会社 アミド化合物およびその用途
JP2011525488A (ja) * 2008-06-20 2011-09-22 ヴァイティー ファーマシューティカルズ,インコーポレイテッド レニン阻害剤およびその使用方法

Also Published As

Publication number Publication date
CN102372653A (zh) 2012-03-14
CN102958912B (zh) 2015-01-14
CN102958912A (zh) 2013-03-06
WO2012019428A1 (zh) 2012-02-16

Similar Documents

Publication Publication Date Title
WO2012024620A3 (en) Autotaxin inhibitors and uses thereof
WO2012021715A3 (en) Stable formulations of linaclotide
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
IL227594A (en) History of Aminobutyric Replaced as Nephrilicin Inhibitors, their Preparation, Pharmaceutical Preparations Containing Them and Their Use in Medication Preparation
MY171577A (en) 2',4'-difluoro-2'-methyl substituted nucleoside derivatives as inhibitors of hcv rna replication
WO2014097151A3 (en) Autotaxin inhibitors
NZ608116A (en) Triazine-oxadiazoles
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
TN2012000465A1 (en) Derivatives of 1-amino-2-cyclopropylethylboronic acid
WO2011086093A3 (en) Pharmaceutical compositions for oral administration of insulin peptides
MX349004B (es) Nuevos compuestos.
IL223795A (en) History of Tetrahydro-Pyrido-Pyrimidine
UA117122C2 (uk) Хінолонові похідні
WO2011017502A3 (en) Linaclotide-containing formulations for oral administration
CA2878796C (en) Derivatives of pyridinone as inhibitors for tissue transglutaminase
WO2012037562A3 (en) Pharmaceutical and nutraceutical compositions of abscisic acid
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
IL213983A (en) Derivatives of pyridazinone that are converted into heteroaryl, their process, their pharmaceutical preparations and their use in the preparation of drugs
IL227024A (en) The 3 heteroarylamino propionic acid derivatives are converted into amino acids, a process for their preparation, their use in the preparation of medicinal preparations and as medical preparations containing them
WO2012019428A8 (zh) 二苯甲醇类衍生物、其制备方法及其在医药上的应用
WO2011123524A3 (en) Macrolide inhibitors of mtor
WO2012099557A3 (en) Fatty acid inhibitors
WO2011125006A3 (en) Sultam compounds
MX351994B (es) Formas cristalinas de [(s)-1-carbamoil-2-(feniil-pirimidin-2-il-am ino)-etil]-amida del acido 2-(2-metilamino-pirimidin-4-il)-1h-indo l-5-carboxilico.
WO2011139255A3 (en) Pharmaceutical compositions comprising cefetamet

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201180005039.7

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11815987

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11815987

Country of ref document: EP

Kind code of ref document: A1